Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.
Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.
A Study of NT-175 in Adult Subjects with Unresectable, Advanced, And/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
-
City of Hope, Duarte, California, United States, 91010
University of California, Los Angeles (UCLA), Los Angeles, California, United States, 90095
Hoag Medical Group, Newport Beach, California, United States, 92663
Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215
Rutgers University, New Brunswick, New Jersey, United States, 09803
Providence Cancer Institute, Portland, Oregon, United States, 97225
Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville, Tennessee, United States, 37203
Baylor Scott & White Medical Center, Dallas, Texas, United States, 75246
MD Anderson Cancer Center, Houston, Texas, United States, 77030
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Neogene Therapeutics, Inc.,
AstraZeneca, STUDY_DIRECTOR, AstraZeneca
2039-08